Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABSTU:8BD 43 EBITDA Margin % is 0.54% as of Jun. 2026, which is 95% below its 10-year median of 11.79. GuruFocus rates STU:8BD with a GF Score™ of 43/100 and a GF Value™ of €0.95. The stock has 2 warning signs investors should review. Among 814 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 57.25% on this metric.
Boule Diagnostics AB (STU:8BD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Boule Diagnostics AB EBITDA Margin % Related Terms
Boule Diagnostics AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:8BD vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (STU:8BD) has a EBITDA Margin % of 0.54% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Boule Diagnostics AB and its competitors. This is 95% below median its historical median of 11.79. According to the industry distribution chart, Boule Diagnostics AB ranks #466 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 57.2%.
Is Boule Diagnostics AB's EBITDA Margin % too high?
Boule Diagnostics AB's current EBITDA Margin % of 0.54% is 95% below median its 10-year median of 11.79. The Medical Devices & Instruments industry median EBITDA Margin % is 7.96. Boule Diagnostics AB's value of 0.54% is 93.2% below this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #466 out of 814 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #466 out of 814 companies for EBITDA Margin %. This places Boule Diagnostics AB in the lower half of its industry. The industry median EBITDA Margin % is 7.96. Boule Diagnostics AB's value of 0.54% is 93.2% below this benchmark. While the company's 10-year median is 11.79 vs. the industry median of 7.96, Boule Diagnostics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.96, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current EBITDA Margin % of 0.54% is 93.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current EBITDA Margin % is 0.54%, which is 95% below median its own 10-year median of 11.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (STU:8BD) has a current EBITDA Margin % of 0.54%. The stock's GF Value™ is €0.95, compared to a current price of €0.48 — trading 49.5% below its estimated fair value. The current EBITDA Margin % is 0.54%, which is 95% below median its 10-year median of 11.79 and 93.2% below the Medical Devices & Instruments industry median of 7.96. Boule Diagnostics AB's overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Boule Diagnostics AB (STU:8BD), the current EBITDA Margin % is 0.54% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (STU:8BD) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of €0.48 is trading 49.5% below its estimated GF Value™ of €0.95.
Key valuation signals for STU:8BD:
EBITDA Margin %: 0.54% (95% below median its 10-year median of 11.79)
GF Value™: €0.95 vs. price of €0.48 (49.5% below fair value)
Industry Position: 93.2% below the Medical Devices & Instruments median (#466 of 814)
No single metric tells the full story. See the STU:8BD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
43GF Score
Get the complete analysis for STU:8BD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:8BD has been successfully added to your 
